

Medical Policy

Dalvance (dalbavancin)	
MEDICAL POLICY NUMBER	MED_Clin_Ops-114
ORIGINAL EFFECTIVE DATE	5/24/2022
CURRENT VERSION NUMBER	2
CURRENT VERSION EFFECTIVE DATE	01/01/2024
APPLICABLE PRODUCT AND MARKET	Individual Family Plan: ALL Small Group: ALL Medicare Advantage: ALL

Brand New Day/Central Health Medicare Plan develops policies and makes coverage determinations using credible scientific evidence including but not limited to MCG™ Health Guidelines, the ASAM Criteria™, and other third party sources, such as peer-reviewed medical literature generally recognized by the relevant medical community, physician specialty society recommendations, and expert opinion as relevant to supplement those sources. Brand New Day/Central Health Medicare Plan Medical Policies, MCG™ Guidelines, and the ASAM Criteria™ are not intended to be used without the independent clinical judgment of a qualified health care provider considering the individual circumstances of each member's case. The treating health care providers are solely responsible for diagnosis, treatment, and medical advice. Members may contact Brand New Day/Central Health Medicare Plan Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Brand New Day/ Central Health Medicare Plan policy may contact the Health Plan. Brand New Day/Central Health Medicare Plan policies and practices are compliant with federal and state requirements, including mental health parity laws.

If there is a difference between this policy and the member specific plan document, the member benefit plan document will govern. For Medicare Advantage members, Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), govern. Refer to the CMS website at <http://www.cms.gov> for additional information.

Brand New Day/Central Health Medicare Plan medical policies address technology assessment of new and emerging treatments, devices, drugs, etc. They are developed to assist in administering plan benefits and do not constitute an offer of coverage nor medical advice. Brand New Day/Central Health Medicare Plan medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Brand New Day/Central Health Medicare Plan does not provide health care services and, therefore, cannot guarantee any results or outcomes. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies are updated based on changes in the evidence and healthcare coding and therefore are subject to change without notice. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). MCG™ and Care Guidelines® are trademarks of MCG Health, LLC (MCG).

PURPOSE

The purpose of this policy is to establish the clinical review criteria that support the determination of medical necessity for Dalvance (dalbavancin) therapy.

POLICY

Prior Authorization and Medical Review is required.

Coverage for Dalvance will be provided for 1 month and may be renewed.

- Max Units (per dose and over time): 1500 mg, administered either as a single dose, -OR- 1000 mg followed one week later by 500 mg

Medical Policy

Initial

- A. Patient has a documented diagnosis of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus) and Enterococcus faecalis (vancomycin susceptible isolates); **AND**
- B. Documentation of a recent culture and sensitivity showing the patient's infection is susceptible to Dalvance; **AND**
- C. Documentation of inadequate treatment response, intolerance, or non-susceptibility report for the current infection to alternative antibiotic treatments including, but not limited to vancomycin; **OR**
- D. Request is for a continuation of therapy that was started at an in-patient setting (within the last 14 days) and member is at time of request transitioning to an outpatient site of care [DISCHARGE DOCUMENTATION REQUIRED WHICH INCLUDES INFECTIOUS DISEASE PRESCRIBER, DURATION OF THERAPY; START AND END DATE].

Renewal

- A. Patient continues to meet initial criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc.; **AND**
- B. Absence of unacceptable toxicity from the drug.

LIMITATIONS/EXCLUSIONS

- 1. Any indication other than those listed above due to insufficient evidence of therapeutic value

DEFINITIONS

- A. DALVANCE (dalbavancin) for injection, for intravenous use. Initial U.S. Approval: 2014

CODING

Applicable NDC Codes	
57970-0100-01	Dalvance 500 mg/vial

Applicable Procedure Code	
J0875	Injection, dalbavancin, 5 mg

Medical Policy

Applicable ICD-10 Codes	
L03.011-L03.019	Cellulitis of finger
L03.031-L03.039	Cellulitis of toe
L03.111-L03.119	Cellulitis of other parts of limb
L03.211	Cellulitis of face
L03.221	Cellulitis of neck
L03.311-L03.319	Cellulitis of trunk
L03.811-L03.818	Cellulitis of other sites
L03.90	Cellulitis, unspecified
A49.02	Methicillin-resistant Staphylococcus aureus infection, unspecified site
B95.62	Methicillin-resistant Staphylococcus aureus infection as the cause of diseases classified elsewhere
A41.01-A41.2	Sepsis due to Staphylococcus
A49.01	Methicillin-susceptible Staphylococcus aureus infection, unspecified site
A49.02	Methicillin-resistant Staphylococcus aureus infection, unspecified site
B95.61-B95.8	Staphylococcus aureus as the cause of diseases classified elsewhere
A40.0-A40.9	Streptococcal sepsis
A49.1	Streptococcal infection, unspecified site
B95.01-B95.1, B95.3-B95.8	Streptococcus

EVIDENCE BASED REFERENCES

1. Product Information: DALVANCE(R) intravenous injection, dalbavancin intravenous injection. Allergan USA Inc (per FDA), Madison, NJ, 2021.

POLICY HISTORY

Original Effective Date	5/24/2022
Revised Date	
P&T Committee Endorsement	5/24/2022
Updated to Brand New Day/Central Health Medicare Plan/Central Health Medicare Plan	01/01/2024

Approved by Pharmacy and Therapeutics Committee

MED_Clin_Ops-114 Dalvance

Confidential & Proprietary

Page 3 of 3